Zhi-hong Chen

发表

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical and translational medicine.

The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer

Jian Su, Jia-Ying Lin, Yi-long Wu, 2009, BMC Cancer.

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Medical Oncology.

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer

T. Mok, Yi-long Wu, Rong Li, 2007, Journal of Cancer Research and Clinical Oncology.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphism of Rs9387478 Correlates with Overall Survival in Female Nonsmoking Patients with Lung Cancer

N. Rothman, Yi-long Wu, Jin-Ji Yang, 2016, The International journal of biological markers.

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

Yi-long Wu, S. An, Xuchao Zhang, 2011, Cancer Chemotherapy and Pharmacology.

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients

Xuchao Zhang, Hong-Hong Yan, Si-pei Wu, 2022, Cancer medicine.

Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer.

Yi-long Wu, S. An, Xuchao Zhang, 2012, Experimental and therapeutic medicine.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

Yi-long Wu, S. An, Jian Su, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Soluble c‐Met Levels Correlated With Tissue c‐Met Protein Expression in Patients With Advanced Non–Small‐Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Clinical lung cancer.

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

Chongrui Xu, Xuchao Zhang, Qian Wu, 2022, JTO clinical and research reports.

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

Yi-long Wu, Xuchao Zhang, S. Dong, 2012, Cancer Chemotherapy and Pharmacology.

Three cases of severe hepatic impairment caused by erlotinib.

Yi-long Wu, S. An, Zhi-hong Chen, 2009, British journal of clinical pharmacology.

[High resolution melting analysis for detecting p53 gene mutations in patients with non-small cell lung cancer].

Yilong Wu, S. An, Xuchao Zhang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Ying Cheng, Yi-long Wu, B. Han, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene Transfer of Calcitonin Gene-Related Peptide Inhibits Macrophages and Inflammatory Mediators in Vein Graft Disease

J. Zhuang, Jian Su, Zhi-hong Chen, 2008 .

Inhibitory effects of calcitonin gene-related peptides on experimental vein graft disease.

J. Zhuang, Jian Su, Zhi-hong Chen, 2010, The Annals of thoracic surgery.

High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.

Yi-long Wu, Chongrui Xu, S. An, 2013, Cancer biomarkers : section A of Disease markers.

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

T. Mok, Yi-long Wu, S. An, 2008, Human pathology.

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2020, Journal of thoracic disease.

Bone metastasis unique plasma exosomal microRNA signature in non-small cell lung cancer

Xue Wu, Y. Shao, Xuchao Zhang, 2019, Journal of Clinical Oncology.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2022, Journal of Cancer Research and Clinical Oncology.

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2016, Oncotarget.

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Thoracic cancer.

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer

Yi-long Wu, Xue Wu, Y. Shao, 2020, Journal for ImmunoTherapy of Cancer.

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

Jin-Ji Yang, K. Yin, Xuchao Zhang, 2023, Cancers.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, European Journal of Cancer.

Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

Yi-long Wu, Jin-Ji Yang, K. Yin, 2021, Translational oncology.

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of Hematology & Oncology.

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

Yi-chen Zhang, Zhi-hong Chen, Qing Zhou, 2022, Frontiers in Oncology.

Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Chinese Medical Journal.

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

T. Mok, Yi-long Wu, Xuchao Zhang, 2009, Pathology & Oncology Research.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2020, Frontiers in Oncology.

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines

Yi-long Wu, S. An, Xuchao Zhang, 2016, PloS one.

Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells

Yi-long Wu, Xuchao Zhang, S. Dong, 2013, PloS one.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2013, Annals of Surgical Oncology.

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2015, Clinical lung cancer.

Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Lung cancer.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, PloS one.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing.

Yi-long Wu, Jin-Ji Yang, Y. Lei, 2015, Journal of genetics and genomics = Yi chuan xue bao.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, The oncologist.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2013, Pathology & Oncology Research.

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

Yi-long Wu, S. An, Xuchao Zhang, 2011, Journal of hematology & oncology.

Single Nucleotide Polymorphisms in VTI1A Gene Contribute to the Susceptibility of Chinese Population to Non-Small Cell Lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, The International journal of biological markers.

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2015, Lung cancer.

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

W. Zhong, S. Dong, Weidong Chen, 2022, Journal for ImmunoTherapy of Cancer.

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2021, Journal of thoracic disease.

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay

Yi-long Wu, W. Zhong, S. An, 2014, Chinese journal of cancer.

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Molecular Cancer.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

Establishment and application of a method of next generation sequencing of 285 genes in lung cancer based on Ion-Proton platform

Xuchao Zhang, Zhi-hong Chen, Wei-bang Guo, 2020, Translational cancer research.

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy

Yi-long Wu, Xuchao Zhang, S. Dong, 2010, Journal of hematology & oncology.

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Clinical Cancer Research.

Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients

Yi-long Wu, S. An, Jian-quan Zhu, 2008 .

Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer

Yi-long Wu, Xue Wu, Y. Shao, 2020, Clinical & Experimental Metastasis.

Heterogeneity in the immune microenvironment of bone metastasis in driver‐positive non‐small cell lung cancer

Weihua Luo, Xuchao Zhang, Dongqin Zhu, 2023, Molecular carcinogenesis.

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Thoracic cancer.

[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].

Zhi-hong Chen, Yadong Wu, 2020, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Distribution and prognosis of uncommon metastases from non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, BMC Cancer.

A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)

W. Mao, Q. Wang, W. Zhong, 2019, Annals of Oncology.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Yi-long Wu, W. Feng, W. Zhong, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2015, Lung cancer.

变性高效液相色谱法检测多种途径获取的非小细胞肺癌组织表皮生长因子受体基因突变

Jin-Ji Yang, Xue-Ning Yang, Yilong Wu, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

Chongrui Xu, Q. Gou, Hong-Hong Yan, 2023, Journal for ImmunoTherapy of Cancer.

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Oncoimmunology.

Identification of a risk score model based on tertiary lymphoid structure‐related genes for predicting immunotherapy efficacy in non‐small cell lung cancer

Chongrui Xu, Zhi-hong Chen, Jia-Qi Liu, 2024, Thoracic cancer.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

Yi-long Wu, S. An, Zhi-hong Chen, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy

S. An, Zhi-hong Chen, Qing Zhou, 2014, Cancer Gene Therapy.

Mutation and polymorphism in the tyrosine kinase domain of KDR in Chinese human lung cancer patients

Yi-long Wu, S. An, Zhi-hong Chen, 2009 .

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Jin-Ji Yang, Xue-Ning Yang, Xuchao Zhang, 2024, Cell reports.